<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180310</url>
  </required_header>
  <id_info>
    <org_study_id>03-364</org_study_id>
    <nct_id>NCT00180310</nct_id>
  </id_info>
  <brief_title>SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System</brief_title>
  <acronym>SPIRIT II</acronym>
  <official_title>A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical
      trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved
      commercially available active control TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
      System.

      TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System is manufactured by Boston
      Scientific.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SPIRIT II trial was a randomized, single blind, active control, multi-center clinical
      evaluation. Subject eligibility criteria were similar to SPIRIT III and enrollment duration
      overlapped between studies. In this study, 300 subjects (3:1 randomization XIENCE V® EECSS:
      TAXUS™ PECSS were enrolled at 31 sites outside the United States. The primary endpoint was
      in-stent late loss at 6 months. Secondary endpoints included clinical outcomes at months 1,
      6, and 9 months and 1, 2, 3, 4 and 5 years; angiographic results at 6 months and 2 years; and
      IVUS results at 6 months and 2 years. Follow-up through 3 years is currently available.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late loss (LL)</measure>
    <time_frame>at 180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-segment Late Loss</measure>
    <time_frame>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent Late Loss at 2 years (for a subset of 152 patients)</measure>
    <time_frame>at 2 years (for a subset of 152 patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal and distal Late Loss</measure>
    <time_frame>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment Angiographic Binary Restenosis (ABR) rate</measure>
    <time_frame>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment percent Diameter Stenosis (% DS)</measure>
    <time_frame>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent percent Volume Obstruction (% VO)</measure>
    <time_frame>at 180 days and at 2 years for a subset of 152 patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque behind the stent( by IVUS)</measure>
    <time_frame>at 180 days and at 2 years for a subset of 152 patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Event (ID-MACE) rate</measure>
    <time_frame>at 30, 180 and 270 days, 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Failure (ID-TVF)</measure>
    <time_frame>at 30, 180 and 270 days, 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>at 30, 180 and 270 days, 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting incomplete stent apposition, late-acquired incomplete stent apposition</measure>
    <time_frame>at 180 days and at 2 years for a subset of 152 patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm, thrombosis and persisting dissection</measure>
    <time_frame>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success(device, procedure and clinical)</measure>
    <time_frame>Acute</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XIENCE V® Everolimus Eluting Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE V® Everolimus Eluting Coronary Stent</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>XIENCE V® Everolimus Eluting Coronary Stent System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease</description>
    <arm_group_label>2</arm_group_label>
    <other_name>TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  De novo Target lesion(s) must be located in a native epicardial vessel with diameter
             between 2.25 mm and 4.25 mm by visual estimate

          -  The target lesion(s) must be in a major artery or branch with a visually estimated
             stenosis of &gt;= 50% and &lt; 100% with a TIMI flow of &gt;= 1

          -  Non-study, percutaneous intervention for lesions in a non-target vessel is allowed if
             done &gt;= 90 days prior to the index procedure or if planned to be done &gt; 9 months after
             the index procedure

        Exclusion Criteria:

          -  De novo target lesion(s) located in a major epicardial vessel or a side branch that
             has been previously treated with any type of percutaneous intervention (e.g., balloon
             angioplasty, stent, cutting balloon, atherectomy) &lt; 9 months prior to index procedure

          -  Target lesion(s) restenotic from previous intervention

          -  Target lesion(s) located in a major epicardial vessel that has been previously treated
             with brachytherapy

          -  Target vessel(s) contains visible thrombus

          -  Patient has a high probability that a procedure other than pre-dilatation, stenting
             and post-dilatation will be required at the time of index procedure for treatment of
             the target vessel (e.g. atherectomy, cutting balloon or brachytherapy)

          -  Patient has additional clinically significant lesion(s) (&gt; 50% diameter stenosis) in a
             target vessel or side branch for which an intervention within 9 months after the index
             procedure may be required
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Serruys</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilheminenspital der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.Z. Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.R. La Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Liège Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Sygehus Syd</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Århus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Hilaire</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Rangueil CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Gatien</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken GmbH</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amper Kliniken AG Klinikum Dachau</name>
      <address>
        <city>Dachau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäßzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Devki Devi Heart &amp; Vascular Institute</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken - Locatie Weezenlanden</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mercy Hospital</name>
      <address>
        <city>Auckland</city>
        <state>Epsom</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <state>Grafton</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cardiology in Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vergelegen Mediclinic</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R.V. Hôpital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, Sudhir K, Boland J, Huber K, Garcia E, te Riele JA; SPIRIT II Investigators. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2009 Dec;2(12):1190-8. doi: 10.1016/j.jcin.2009.10.002.</citation>
    <PMID>20129545</PMID>
  </reference>
  <results_reference>
    <citation>Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention. 2006 Nov;2(3):286-94.</citation>
    <PMID>19755303</PMID>
  </results_reference>
  <results_reference>
    <citation>Ruygrok PN, Desaga M, Van Den Branden F, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys PW. One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. EuroIntervention. 2007 Nov;3(3):315-20.</citation>
    <PMID>19737711</PMID>
  </results_reference>
  <results_reference>
    <citation>Khattab AA, Richardt G, Verin V, Kelbaek H, Macaya C, Berland J, Miquel-Hebert K, Dorange C, Serruys PW. Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial. EuroIntervention. 2008 Mar;3(5):566-73.</citation>
    <PMID>19608482</PMID>
  </results_reference>
  <results_reference>
    <citation>Wiemer M, Seth A, Chandra P, Neuzner J, Richardt G, Piek JJ, Desaga M, Macaya C, Bol CJ, Miquel-Hebert K, De Roeck K, Serruys PW. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. Am Heart J. 2008 Oct;156(4):751.e1-7. doi: 10.1016/j.ahj.2008.07.005.</citation>
    <PMID>18926156</PMID>
  </results_reference>
  <results_reference>
    <citation>SPIRIT II study: A clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. Serruys Patrick W (Reprint). Erasmus MC, Ctr Thorax, Rotterdam, Netherlands. Journal of the American College of Cardiology 51 ( 10, Suppl. A ): p A261 MAR 11 2008</citation>
  </results_reference>
  <results_reference>
    <citation>A clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with cle novo native coronary artery lesions. Ruygrok Peter(Reprint). Auckland City Hosp, Auckland, New Zealand Journal: Journal of the American College of Cardiology 49 ( 9, Suppl. B ): p 28B-29B MAR 6 2007 2007 i2 Summit 2007 on Innovation in Intervention New Orleans, LA, USA March 24 -27, 2007; 20070324 ISSN: 0735-1097</citation>
  </results_reference>
  <results_reference>
    <citation>A clinical evaluation of the XIENCE V Everolimus Eluting CSS in the treatment of patients with de novo, native coronary artery lesions. Pharmaco kinetic substudy. Seth A (Reprint); Neuzner J; Richardt G; Wiemer M; Piek J J; Desaga M; Macaya C; Serruys P W; Spirit II Investigators (Reprint) Author Address: Max Hosp, Vasc Inst, New Delhi, India. European Heart Journal 27 ( Suppl. 1 ): p 767 AUG 2006 2006 World Congress of Cardiology Barcelona, SPAIN September 02 -06, 2006; 20060902 ISSN: 0195-668X Document Type: Meeting; Meeting Poster</citation>
  </results_reference>
  <results_reference>
    <citation>Serruys, P. SPIRIT II Study: A Clinical Evaluation of the XIENCE™ V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions. European Society of Cardiology - ESC Congress 2006</citation>
  </results_reference>
  <results_reference>
    <citation>Serruys, P. SPIRIT II Clinical Study: A clinical evaluation of the XIENCE™ V Everolimus Eluting CSS in the treatment of patients with de novo, native coronary artery lesions - IVUS substudy. Transcatheter Cardiovascular Therapeutics - TCT Congress 2006</citation>
  </results_reference>
  <results_reference>
    <citation>Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, Suttorp MJ, Tijssen JG, Miquel-Hebert K, Veldhof S, Henriques JP, Serruys PW, Piek JJ. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv. 2009 Aug;2(4):339-47. doi: 10.1161/CIRCINTERVENTIONS.108.831800.108.831800. Epub 2009 Jul 22.</citation>
    <PMID>20031737</PMID>
  </results_reference>
  <results_reference>
    <citation>Onuma Y and Serruys P. The SPIRIT II Study - A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions: 4 Year Clinical Results. American College of Cardiology - ACC '10&amp; i2 Summit 2010.</citation>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kathleen Peeters</name_title>
    <organization>Abbott Vascular</organization>
  </responsible_party>
  <keyword>drug eluting stents</keyword>
  <keyword>stents</keyword>
  <keyword>angioplasty</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>total coronary occlusion</keyword>
  <keyword>coronary artery restenosis</keyword>
  <keyword>stent thrombosis</keyword>
  <keyword>vascular disease</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>coronary artery stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

